GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation

Nature Communications

Volumn 7, Issue , 2016, Pages

  Liu, Weiqing ^a   Zhou, Liyan ^a   Zhou, Chenchen ^a   Zhang, Shiwen ^a   Jing, Junjun ^a   Xie, Liang ^a   Sun, Ningyuan ^a   Duan, Xiaobo ^a   Jing, Wei ^a   Liang, Xing ^a   Zhao, Hu ^a   Ye, Ling ^a   Chen, Qianming ^a   Yuan, Quan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH DIFFERENTIATION FACTOR; GROWTH DIFFERENTIATION FACTOR 11; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; SMAD2 PROTEIN; SMAD3 PROTEIN; UNCLASSIFIED DRUG;

BONE; DIFFERENTIATION; DISEASE INCIDENCE; PROTEIN; RODENT;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEFECT; BONE MASS; BONE REGENERATION; BONE REMODELING; CELL DIFFERENTIATION; CONTROLLED STUDY; ESTROGEN DEFICIENCY; FEMALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN FUNCTION; PROTEIN INDUCTION; YOUNG ADULT;

MUS;

EID: 84988583593     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12794     Document Type: Article

References (64)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285, 785-795 (2001).
2. Rachner, T. D., Khosla, S. & Hofbauer, L. C. Osteoporosis: now and the future. Lancet 377, 1276-1287 (2011).
3. Crane, J. L. & Cao, X. Bone marrow mesenchymal stem cells and TGF-beta signaling in bone remodeling. J. Clin. Invest. 124, 466-472 (2014).
4. Zaidi, M. Skeletal remodeling in health and disease. Nat. Med. 13, 791-801 (2007).
5. Manolagas, S. C. & Parfitt, A. M. What old means to bone. Trends Endocrinol. Metab. 21, 369-374 (2010).
6. Raisz, L. G. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J. Clin. Invest. 115, 3318-3325 (2005).
7. Raggatt, L. J. & Partridge, N. C. Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem. 285, 25103-25108 (2010).
8. Yu, B. et al. Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-kappaB. Nat. Med. 20, 1009-1017 (2014).
9. Nakashima, M., Toyono, T., Akamine, A. & Joyner, A. Expression of growth/ differentiation factor 11, a new member of the BMP/TGFbeta superfamily during mouse embryogenesis. Mech. Dev. 80, 185-189 (1999).
10. Rahman, M. S., Akhtar, N., Jamil, H. M., Banik, R. S. & Asaduzzaman, S. M. TGF-beta/BMP signaling and other molecular events: Regulation of osteoblastogenesis and bone formation. Bone Res. 3, 15005 (2015).
11. Quinn, J. M. et al. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J. Bone Miner. Res. 16, 1787-1794 (2001).
12. Sells Galvin, R. J., Gatlin, C. L., Horn, J. W. & Fuson, T. R. TGF-beta enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem. Biophys. Res. Commun. 265, 233-239 (1999).
13. Bonewald, L. F. & Dallas, S. L. Role of active and latent transforming growth factor beta in bone formation. J. Cell. Biochem. 55, 350-357 (1994).
14. Breen, E. C. et al. TGF beta alters growth and differentiation related gene expression in proliferating osteoblasts in vitro, preventing development of the mature bone phenotype. J. Cell. Physiol. 160, 323-335 (1994).
15. Alliston, T., Choy, L., Ducy, P., Karsenty, G. & Derynck, R. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J. 20, 2254-2272 (2001).
16. Dankbar, B. et al. Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice. Nat. Med. 21, 1085-1090 (2015).
17. McPherron, A. C., Lawler, A. M. & Lee, S. J. Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11. Nat. Genet. 22, 260-264 (1999).
18. Oh, S. P. et al. Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning. Genes Dev. 16, 2749-2754 (2002).
19. Li, Z. et al. Transgenic overexpression of bone morphogenetic protein 11 propeptide in skeleton enhances bone formation. Biochem. Biophys. Res. Commun. 416, 289-292 (2011).
20. Nakashima, M., Mizunuma, K., Murakami, T. & Akamine, A. Induction of dental pulp stem cell differentiation into odontoblasts by electroporationmediated gene delivery of growth/differentiation factor 11 (Gdf11). Gene Ther. 9, 814-818 (2002).
21. Nakashima, M. et al. Stimulation of reparative dentin formation by ex vivo gene therapy using dental pulp stem cells electrotransfected with growth/ differentiation factor 11 (Gdf11). Hum. Gene Ther. 15, 1045-1053 (2004).
22. Loffredo, F. S. et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 153, 828-839 (2013).
23. Katsimpardi, L. et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 344, 630-634 (2014).
24. Sinha, M. et al. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science 344, 649-652 (2014).
25. Poggioli, T. et al. Circulating growth differentiation factor 11/8 levels decline with age. Circ. Res. 118, 29-37 (2016).
26. Schafer, M. J. et al. Quantification of GDF11 and myostatin in human aging and cardiovascular disease. Cell Metab. 23, 1207-1215 (2016).
27. Egerman, M. A. et al. GDF11 increases with age and inhibits skeletal muscle regeneration. Cell Metab. 22, 164-174 (2015).
28. Glass, D. J. Elevated GDF11 is a risk factor for age-related frailty and disease in humans. Cell Metab. 24, 7-8 (2016).
29. Smith, S. C. et al. GDF11 does not rescue aging-related pathological hypertrophy. Circ. Res. 117, 926-932 (2015).
30. Omata, Y. et al. Genomewide comprehensive analysis reveals critical cooperation between Smad and c-Fos in RANKL-induced osteoclastogenesis. J. Bone Miner. Res. 30, 869-877 (2015).
31. Kang, J. S., Alliston, T., Delston, R. & Derynck, R. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. EMBO J. 24, 2543-2555 (2005).
32. Ehnert, S. et al. Transforming growth factor beta1 inhibits bone morphogenic protein (BMP)-2 and BMP-7 signaling via upregulation of Ski-related novel protein N (SnoN): Possible mechanism for the failure of BMP therapy? BMC Med. 10, 101 (2012).
33. Gronroos, E. et al. Transforming growth factor beta inhibits bone morphogenetic protein-induced transcription through novel phosphorylated Smad1/5-Smad3 complexes. Mol. Cell Biol. 32, 2904-2916 (2012).
34. Hayashi, M. et al. Osteoprotection by semaphorin 3A. Nature 485, 69-74 (2012).
35. Scudellari, M. Ageing research: blood to blood. Nature 517, 426-429 (2015).
36. Sun, H. & Wang, Y. The elusive philosopher's stone in young blood. Circ. Res. 117, 906-908 (2015).
37. Kaiser, J. 'Rejuvenation factor' in blood turns back the clock in old mice. Science 344, 570-571 (2014).
38. Olson, K. A. et al. Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: Analysis of the Heart and Soul and HUNT3 cohorts. Eur. Heart J. 36, 3426-3434 (2015).
39. Brun, C. E. & Rudnicki, M. A. GDF11 and the mythical fountain of youth. Cell Metab. 22, 54-56 (2015).
40. Rodgers, B. D. & Eldridge, J. A. Reduced circulating GDF11 is unlikely responsible for age-dependent changes in mouse heart, muscle, and brain. Endocrinology 156, 3885-3888 (2015).
41. Harper, S. C. et al. Is growth differentiation factor 11 a realistic therapeutic for aging-dependent muscle defects? Circ. Res. 118, 1143-1150 (2016).
42. Hinken, A. C. et al. Lack of evidence for GDF11 as a rejuvenator of aged skeletal muscle satellite cells. Aging Cell 15, 582-584 (2016).
43. Rodgers, B. D. The immateriality of circulating GDF11. Circ. Res. 118, 1472-1474 (2016).
44. Li, Z., Kawasumi, M., Zhao, B., Moisyadi, S. & Yang, J. Transgenic over-expression of growth differentiation factor 11 propeptide in skeleton results in transformation of the seventh cervical vertebra into a thoracic vertebra. Mol. Reprod. Dev. 77, 990-997 (2010).
45. Ge, G., Hopkins, D. R., Ho, W. B. & Greenspan, D. S. GDF11 forms a bone morphogenetic protein 1-activated latent complex that can modulate nerve growth factor-induced differentiation of PC12 cells. Mol. Cell Biol. 25, 5846-5858 (2005).
46. Zhang, Y. et al. Growth differentiation factor 11 is a protective factor for osteoblastogenesis by targeting PPARgamma. Gene 557, 209-214 (2015).
47. McPherron, A. C., Huynh, T. V. & Lee, S. J. Redundancy of myostatin and growth/differentiation factor 11 function. BMC Dev. Biol. 9, 24 (2009).
48. Brotto, M. & Bonewald, L. Bone and muscle: Interactions beyond mechanical. Bone 80, 109-114 (2015).
49. Brotto, M. & Johnson, M. L. Endocrine crosstalk between muscle and bone. Curr. Osteoporos. Rep. 12, 135-141 (2014).
50. Cianferotti, L. & Brandi, M. L. Muscle-bone interactions: basic and clinical aspects. Endocrine 45, 165-177 (2014).
51. Gamer, L. W., Cox, K. A., Small, C. & Rosen, V. Gdf11 is a negative regulator of chondrogenesis and myogenesis in the developing chick limb. Dev. Biol. 229, 407-420 (2001).
52. Esquela, A. F. & Lee, S. J. Regulation of metanephric kidney development by growth/differentiation factor 11. Dev. Biol. 257, 356-370 (2003).
53. Hamrick, M. W. et al. Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. Bone 40, 1544-1553 (2007).
54. Hamrick, M. W. Increased bone mineral density in the femora of GDF8 knockout mice. Anat. Rec. A Discov. Mol. Cell Evol. Biol. 272, 388-391 (2003).
55. Hamrick, M. W., Pennington, C. & Byron, C. D. Bone architecture and disc degeneration in the lumbar spine of mice lacking GDF-8 (myostatin). J. Orthop. Res. 21, 1025-1032 (2003).
56. Bouxsein, M. L. et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res. 25, 1468-1486 (2010).
57. Yuan, Q. et al. Increased osteopontin contributes to inhibition of bone mineralization in FGF23-deficient mice. J. Bone Miner. Res. 29, 693-704 (2014).
58. Dempster, D. W. et al. Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 28, 2-17 (2013).
59. Song, L. et al. Loss of wnt/beta-catenin signaling causes cell fate shift of preosteoblasts from osteoblasts to adipocytes. J. Bone Miner. Res. 27, 2344-2358 (2012).
60. Yuan, Q. et al. Deletion of PTH rescues skeletal abnormalities and high osteopontin levels in Klotho-/-mice. PLoS Genet. 8, e1002726 (2012).
61. Wu, X. et al. Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell 7, 571-580 (2010).
62. Liu, W. et al. Effect of resorbable collagen plug on bone regeneration in rat critical-size defect model. Implant Dent. 25, 163-170 (2016).
63. Liu, W. et al. Chronic kidney disease impairs bone defect healing in rats. Sci. Rep. 6, 23041 (2016).
64. Spicer, P. P. et al. Evaluation of bone regeneration using the rat critical size calvarial defect. Nat. Protoc. 7, 1918-1929 (2012).